ARTICLE | Clinical News
ATI-50001: Ph I started
January 5, 2017 9:56 PM UTC
Aclaris began a Phase I trial to evaluate oral ATI-50001 in 12 healthy volunteers. Aclaris has exclusive, worldwide rights to ATI-50001 from Rigel under a 2015 deal (see BioCentury, Sept. 14, 2015)....